Think It’s Too Late to Buy This Leading Biotech Stock? Here’s Why There’s Still Time.
The market may have been too quick to dismiss this biotech’s pipeline prospects after a recent trial result. The market was less than impressed with the top-line results from Viking Therapeutics‘ (VKTX 1.73%) phase 2 trial of an oral formulation of its anti-obesity drug VK2735. The disappointment created the sense that the stock lacks any […]
Think It’s Too Late to Buy This Leading Biotech Stock? Here’s Why There’s Still Time. Read More »